BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 3079490)

  • 1. Current status and future directions of clinical trials in chronic lymphocytic leukemia.
    Nerenstone SR; Archer JI; Cheson BD
    Oncology (Williston Park); 1987 Oct; 1(8):31-40, 44. PubMed ID: 3079490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pentostatin (Nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia.
    Waselenko JK; Grever MR; Beer M; Lucas MA; Byrd JC
    Semin Oncol; 2000 Apr; 27(2 Suppl 5):44-51. PubMed ID: 10877052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging therapy for chronic lymphocytic leukaemia.
    Auer RL; Gribben J; Cotter FE
    Br J Haematol; 2007 Dec; 139(5):635-44. PubMed ID: 17961187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.
    O'Brien S; Moore JO; Boyd TE; Larratt LM; Skotnicki A; Koziner B; Chanan-Khan AA; Seymour JF; Bociek RG; Pavletic S; Rai KR
    J Clin Oncol; 2007 Mar; 25(9):1114-20. PubMed ID: 17296974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bendamustine in the treatment of chronic lymphocytic leukemia.
    Knauf W
    Expert Rev Anticancer Ther; 2009 Feb; 9(2):165-74. PubMed ID: 19192955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia.
    Tsimberidou AM; Kantarjian HM; Cortes J; Thomas DA; Faderl S; Garcia-Manero G; Verstovsek S; Ferrajoli A; Wierda W; Alvarado Y; O'Brien SM; Albitar M; Keating MJ; Giles FJ
    Cancer; 2003 Apr; 97(7):1711-20. PubMed ID: 12655528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in the treatment of B-cell chronic lymphocytic leukemia.
    Cheson BD
    Oncology (Williston Park); 1990 Sep; 4(9):71-8, 83-4; disc. 84, 87-8, 90 pass. PubMed ID: 2145022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal antibodies in chronic lymphocytic leukemia.
    Ferrajoli A; Faderl S; Keating MJ
    Expert Rev Anticancer Ther; 2006 Sep; 6(9):1231-8. PubMed ID: 17020457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent progress in the management of chronic lymphocytic leukemia.
    Robak T
    Cancer Treat Rev; 2007 Dec; 33(8):710-28. PubMed ID: 17904294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variations on the fludarabine, cyclophosphamide, and rituximab combination in chronic lymphocytic leukemia therapy: what have we learned?
    Ahmadi T; Schuster SJ
    J Clin Oncol; 2009 Feb; 27(4):479-80. PubMed ID: 19075263
    [No Abstract]   [Full Text] [Related]  

  • 11. [Treatment of chronic lymphatic leukemia].
    Adam Z; Vorlícek J; Hejlová N
    Vnitr Lek; 1996 Aug; 42(8):573-8. PubMed ID: 8967031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population.
    Perkins JG; Flynn JM; Howard RS; Byrd JC
    Cancer; 2002 Apr; 94(7):2033-9. PubMed ID: 11932906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in the diagnosis and treatment of chronic lymphocytic leukemia.
    Abbott BL
    Clin Adv Hematol Oncol; 2004 Jul; 2(7):448-54. PubMed ID: 16163221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic approaches to chronic lymphocytic leukemia.
    Robertson LE; Keating MJ
    Tex Med; 1991 Nov; 87(11):68-74. PubMed ID: 1759245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The place of cladribine in the treatment of chronic lymphocytic leukemia: a 10-year experience in Poland.
    Robak T
    Ann Hematol; 2005 Feb; 84(2):63-70. PubMed ID: 15558283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pentostatin in chronic lymphocytic leukemia.
    Sauter C; Lamanna N; Weiss MA
    Expert Opin Drug Metab Toxicol; 2008 Sep; 4(9):1217-22. PubMed ID: 18721115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flavopiridol in chronic lymphocytic leukemia: a concise review.
    Christian BA; Grever MR; Byrd JC; Lin TS
    Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S179-85. PubMed ID: 19778838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal antibody therapy of chronic lymphocytic leukemia.
    Mavromatis B; Cheson BD
    J Clin Oncol; 2003 May; 21(9):1874-81. PubMed ID: 12721266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of fludarabine, cyclophosphamide/doxorubicin/prednisone, and cyclophosphamide/doxorubicin/vincristine/prednisone in advanced forms of chronic lymphocytic leukemia: preliminary results of a controlled clinical trial. The French Cooperative Group on Chronic Lymphocytic Leukemia.
    Semin Oncol; 1993 Oct; 20(5 Suppl 7):21-3. PubMed ID: 8235691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia.
    Tsimberidou AM; Keating MJ; Giles FJ; Wierda WG; Ferrajoli A; Lerner S; Beran M; Andreeff M; Kantarjian HM; O'Brien S
    Cancer; 2004 Jun; 100(12):2583-91. PubMed ID: 15197800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.